Besaratinia A, Bates SE, Synold TW, Pfeifer GP. Similar mutagenicity of photoactivated porphyrins and ultraviolet A radiation mouse embryonic fibroblasts: Involvement of oxidative DNA lesions in mutagenesis. Biochemistry; 2004, 43(49): 15557-15566.

Besaratinia A, Synold TW, Xi BX, Pfeifer GP. G-to-T transversions and small tandem base deletions are the hallmark of mutations induced by ultraviolet a radiation in mammalian cells. Biochemistry; 2004, 43(25): 8169-8177.

Buettner VL, Longmate JA, Barish ME, Mann JR, Singer SJ. Analysis of imprinting in mice with uniparental duplication of proximal chromosomes 7 and 15 by use of a custom oligonucleotide microarray. Mammalian Genome; 2004, 15(3): 199-209.

Cao W, Chen XF, Dai HF, Shen BH, Chu D, McAfee T, Zhang ZF. Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cancer; 2004, 101(4): 834-844.

Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al KZ, Leong L, Lim D, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. Cancer Chemotherapy and Pharmacology; 2004, 54(3): 241-248.

Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, Doroshow JH. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Research; 2004, 64(3): 962-968.

Chu FF, Esworthy RS, Doroshow JH. Role of se-dependent glutathione peroxidase in gastrointestinal inflammation and cancer. Free Rad. Biol. Med.; 2004; 36: 1481-1495.

Grant M, Ferrell B, Dean G, Uman G, Chu D, Krouse R. Revision and psychometric testing of the City of Hope Quality of Life Ostomy Questionnaire. Quality of Life Research; 2004, 13(8): 1445-1457.

Holleran JL, Fourcade J, Egorin MJ, Eiseman JL, Parise RA, Musser SM, White KD, Covey JM, Forrest GL, Pan SS. In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase. Drug Metabolism and Disposition; 2004, 32(5): 490-496.

Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma - Final results from the California Cancer Consortium Screening and Phase II trial. Cancer; 2004, 100(10): 2125-2131.

Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim KM, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clinical Cancer Research; 2004, 10(3): 924-928.

Liu XY, Zhou BS, Xue LJ, Qiu WH, Shih J, Zheng S, Yen Y. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. Biochemical Pharmacology; 2004, 67(8): 1499-1511.

Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, Forman S, Margolin K, Morgan R, Shibata S, Somlo G. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: Lack of neuroprotective effect of amifostine. Clinical Cancer Research; 2004, 10(2): 461-467.

Qiu WH, Zhou BS, Zou HZ, Liu XY, Chu PG, Lopez R, Shih J, Chung C, Yen Y. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. American Journal of Pathology; 2004, 165(5): 1689-1699.

Rodriguez R, Parker P, Nademanee A, Smith D, O'Donnell MR, Stein A, Snyder DS, Fung HC, Krishnan AY, Popplewell L, Cohen S, Somlo G, Angelopoulou M, Al KZ, Falk PM, Spielberger R, Kogut N, Sahebi F, Senitzer D, Slovak M, Schriber J, Forman SJ. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplantation; 2004, 33(11): 1123-1129.

Shao JM, Zhou BS, Zhu LJ, Qiu WH, Yuan YC, Xi BX, Yen Y. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Research; 2004, 64(1): 1-6.

Shibata SI, Pezner R, Chu D, Doroshow JH, Chow WA, Leong LA, Margolin KA, McNamara MV, Morgan RJ, Raschko JW, Somlo G, Tetef ML, Yen Y, Synold TW, Wagman L, Vora N, Carroll M, Lin S, Longmate J. A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies. Ejso; 2004, 30(6): 650-657.

Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R, Shibata S, Chu PG, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Yen Y, Damon L, Doroshow JH. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose intense chemotherapy. Journal of Clinical Oncology; 2004, 22(10): 1839-1848.

Trisal V, Qian D, Wagman LD. Axillary recurrence in DCIS: Is axillary lymphadenectomy warranted?. American Surgeon; 2004, 70(10): 876-880.

Wang ZD, La RC, Mekhoubad S, Lacey SF, Villacres M C, Markel S, Longmate J, Ellenhorn JD, Siliciano RF, Buck C, Britt WJ, Diamond DJ. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood; 2004, 104(3): 847-856.

Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA. Pilot trial evaluating an I-123-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clinical Cancer Research; 2004, 10(15): 5014-5021.

Yen Y, Chu PG, Feng W. Parathyroid hormone-related hypercalcemia in cholangiocarcinoma. Journal of Clinical Oncology; 2004, 22(11): 2244-2245.

Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemotherapy & Pharmacology; 2004, 54(4): 283-9.

Klevecz RR, Bolen J, Forrest G, Murray DB. A genomewide oscillation in transcription gates DNA replication and cell cycle.[see comment]. Proceedings of the National Academy of Sciences of the United States of America; 2004, 101(5): 1200-5.

Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, Ramin SA, Kawachi MH, Smith SS. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology; 2004, 64(4): 821-825.

Chen S. Anticancer activities of white button mushrooms. Journal of Nutrition; 2004, 134(12): 3532S-3533S.

Wang Y, Chan FL, Chen S, Leung LK. The plant polyphenol butein inhibits estrogen synthesis. Faseb Journal; 2004, 18(4): A127-A127.

Chen S, Cho M, Karlsberg K, Zhou D, Yuan YC. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J Biol Chem; 2004, 279(46): 48071-8.

Zhou D, Chen B, Ye JJ, Chen S. A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction. Oncogene; 2004, 23(31): 5394-404.

Pun SH, Tack F, Bellocq NC, Cheng JJ, Grubbs BH, Jensen GS, Davis ME, Brewster M, Janicot M, Janssens B, Floren W, Bakker A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biology & Therapy; 2004, 3(7): 641-650.

Heidel JD, Hu SW, Liu XF, Triche TJ, Davis ME. Lack of interferon response in animals to naked siRNAs. Nature Biotechnology; 2004, 22(12): 1579-1582.

Cheng J, Khin K, Davis ME. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Molecular Pharmaceutics; 2004, 1(3): 183-93.

Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews Drug Discovery; 2004, 3(12): 1023-35.

Bellocq NC, Kang DW, Wang X, Jensen GS, Pun SH, Schluep T, Zepeda ML, Davis ME. Synthetic biocompatible cyclodextrin-based constructs for local gene delivery to improve cutaneous wound healing. Bioconjugate Chemistry; 2004, 15(6): 1201-11.

Al RW, Ali MW, Chu DZ, Paz IB, Blair SL. Clear cell sarcoma in the era of sentinel lymph node mapping. Journal of Surgical Oncology; 2004, 87(3): 126-129.

Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide - A children's cancer group and pediatric oncology group study. Journal of Clinical Oncology; 2004, 22(14): 2873-2876.

Cullinane CA, Paz IB, Smith D, Carter N, Grannis FW. Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest; 2004, 125(4): 1328-1334.

Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara DR, Gumerlock PH. Mutant DNA in plasma of lung cancer patients - Potential for monitoring response to therapy. Circulating Nucleic Acids in Plasma/Serum Iii and Serum Proteomics; 2004; 1022: 55-60.

Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, Sznol M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemotherapy and Pharmacology; 2004, 54(4): 331-342.